NIHR BioResource Centre Leeds
The NIHR BioResource Centre Leeds, led by Maya Buch, sits within the wider NIHR infrastructure at the Leeds Teaching Hospitals NHS Trust (LTHT) and is committed to delivering research to transform the outcomes and lives of people with a range of rare and common diseases.
Ultimately responsible to the LTHT Executive, the BioResource comprises a core management team consisting of Prof Maya Buch (Bioresource Centre Director), Chris Herbert (Director of Operations, Research & Innovation) and Debbie Beirne (Clinical Research Facility (CRF) Manager). This team has developed an effective strategy that is well-aligned with Leeds’ NIHR research ambition. The operational group consisting of Maya Buch, Debbie Beirne, Maxine Berry (Project Support Manager), George Twigg (IT Lead) and Clinical Trials Assistants meet on a monthly basis to ensure successful implementation of the BioResource plans, appraise progress, and identify any issues in need of resolving. This group works closely with the relevant disease and specialty leads.
The BioResource’s overarching vision is to use this invaluable resource through academic-led initiatives and other NIHR programmes such as the Translational Research Collaborations, and build on the highly successful patient-focused translational research that spans the core themes and research pillars of the NIHR Leeds Biomedical Research Centre (BRC) and CRF. This includes Musculoskeletal Diseases (with us leading on the rare disease systemic sclerosis), Cardiovascular, Oncology and Paediatrics. We also aim to provide a platform for our wider clinical and research strengths. By contributing to this important national initiative, we hope to efficiently translate refined scientific investigation to direct patient benefit. To find out more visit: NIHR BioResource.
Exciting new opportunity to engage in anxiety/depression research
Depression and anxiety (including OCD, BDD, and other related disorders) are common but complex disorders whose research needs very large sample sizes. The Genetic Links to Anxiety and Depression (GLAD) study launches this September and aims to recruit >40,000 individuals. Anyone age 16 years or older who has experienced one or more of these disorders during their lives can join this recontactable database to facilitate future research. Participants will also join a national Mental Health BioResource and contribute to the largest ever single study of anxiety and depression.
All enrollment takes place online at the GLAD website. An online animation explains the consent process with more detailed information in text format. Once you have provided consent and completed an online questionnaire you will be sent a saliva DNA sample kit to enable genetic studies.